$25m non-refundable cash payment for a 13 month option to develop IV.If exercised, $20m cash payment, 2% to 5% royalty based on FOB revenue derived by FMG.FMG pays all costs of development.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025
OAR Chris Judd's Talk Ya Book: Orthocell building on 'enormous potential' with steady growth - and US push to come